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Conclusion: CNS bacteraemia is most commonly 
associated with intravenous catheter infection, which 
was predominantly seen. Oro-pharyngeal colonization 
does account for a significant (29.4%) incidence of 
bacteraemia in the compromised host including neutro- 
penic and bone marrow transplant (autograft) recipients. 
Hence, prophylaxis with antibiotic is essential. 
A break up of the percentage of bacterial isolates to 
be presented. 
The estimation of dendritic cells function in children 
immunocompromised after chemotherapy of 
hematological malignancies 
J. Weclawek-Tompol, A. Chybicka, 
B. Rybka, R. Ryczan, D. Noworolska, 
J. Boguslawska-Jaworska 
Department of Children Hematology 
and Oncology, Medical University 
of Wroclaw, Poland 
Dendritic cells are rare cells that are principally involved 
in the presentation of antigen and stimulation of T 
lymphocytes. In chemotherapy treatment of neoplasms 
is bind with depreciated of immunological potential of 
patient. Development and function of dendritic cells 
may be inhibited by cytokines produced by cancer cells. 
The total number of 34 patients: 23 males and 11 
females, aged from 16 months to 17 years (median 11 
years) treated in the Department of Children Oncology 
and Hematology Medical University of Wroclaw, Poland 
(ALL-15 AML-9, NHL-2, HD-5, LCAL-3 children) 
were examined. Peripheral blood was collect at time of 
diagnosis and during chemotherapy and analyzed with 
used flow cytometric analysis. Concentration of a 
dendritic cells (CDllc+HLA DR+CD83+ CD86+) 
were examined. Phenotypic populations of elementary 
lymphocytes (CD3, CD4, CD8, CD16, CD19, CD56) 
with take into consideration markers of activation 
CD23, CD26, CD28, HLA-DR was analyzed. 
The dendritic cells were examined with use of specific 
markers for distinct blood dendritic cell populations: 
BDCA-1 (antigen presented on CD1lchish and CD123’“” 
dendritic cells with monocytoid morphology); BDCA-2 
(expression on CDllc- and CD123’ dendritic cells with 
plasmocytoid morphology); BDCA-3 (expression on 
CDlldim and CD123- dendritic cells with monocytoid 
morphology). 
The results of our study showed decreased level of 
blood the dendritic cells in our patients in comparison 
with control group of healthy children. 
Results of study were compared with reply of 
antineoplasm treatment. 
Work supported by grant 131 and 138. 
Nosocomial Candidu guilliermondii fungemia in 
cancer patients 
Masoud Mardani, Hend A. Hanna, Essam Girgany, 
R. M. D. lssam 
The University of Texas M. D. Anderson Cancer 
Center, Houston, TX, USA 
Candida guilliermondii is rarely isolated from humans, 
but is considered a part of the emerging opportunistic 
fungi being recovered more frequently from severely 
immunocompromised patients. From January 1988 to 
December 1998 we identified 9 patients with C. guillier- 
mondii fungemia at our center. Most of the fungemias 
(5/9) occurred as a breakthrough infection on antifungal 
prophylaxis with agents such as fluconazole, Iiposomal 
amphotericin B, and itraconazole. Five of the 9 patients 
acquired the infection during their hospital stay 10-45 
days after admission and were considered as noso- 
comial, while the remaining 4 patients acquired the 
infection endogenously within O-4 days following admis- 
sion. Nosocomial fungemia was associated with hemato- 
logical malignancy most often occurring in leukemia 
patients in relapse, prior intensive chemotherapy, 
profound neutropenia, mucositis, steroid therapy, and 
concomitant multiple bacterial and fungal sepsis. Non- 
nosocomial fungemias were more often associated with 
solid tumors or hematological malignancy in remission, 
without steroids or mucositis, Both groups were treated 
with azoles and amphotericin compounds with variable 
outcomes. Four of the five patients in the nosocomial 
group died, while the only patient who survived had 
catheter-related fungemia. In contrast, all of the non- 
nosocomial cases survived the fungemia despite the fact 
that half of them (2/4) did not receive any treatment. 
Within the limitations of a small number, nosocomial 
C. guilliermondii fungemia occurring in the setting of 
hematologic malignancy and profound neutropenia 
is often a breakthrough infection with poor outcome 
despite aggressive antifungal therapy. 
Candida glabrata fungemia in immunocompromised 
cancer patients: epidemiology and outcome analysis 
M. Mardani, H. Hanna, J. Abbas, A. Al Rahwan, 
R. Hachem, I. Raad 
University of Texas M. D. Anderson Cancer Center, 
Houston, TX, USA 
Between January 1993 and May 1998, we identified 
76 immunocompromised cancer patients (pts) with 
Candida glabrata fungemia. With the widespread use 
of fluconazole prophylaxis in 1992 at our center, the 
incidence of C. glabrata fungemia increased. Most im- 
munocompromised cancer pts with C. glabrata fungemia 
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were neutropenic (47%). The underlying disease was 
leukemia (47%) solid tumor (38%), and lymphoma 
(16%). Most (64%) of these pts with C. glabrata fungemia 
received fluconazole prophylaxis prior to the onset of 
fungemia. Disseminated infection occurred in 37 pts 
(39%), while 15% of all C. glabrata fungemia infections 
were catheter-related. Breakthrough candidemia on 
amphotericin B or liposomal compound regimen occur- 
red in 10 pts, 5 of whom had disseminated infection. C. 
glabrata fungemia was the primary cause of death in 13 
pts (14%) and was a contributory factor to death in 29 
other pts (39%). In conclusion, C. glabrata fungemia in 
immunocompromised cancer pts is associated with a high 
frequency of dissemination and mortality. This infection 
should be considered in any febrile neutropenic immuno- 
compromised cancer pt receiving fluconazole. 
The treatment of febrile neutropenia (FN) in children 
with hematological malignancies 
N. Dmitrieva, L. Ivanova, N. Baguirova, N?,N. Blokhin 
Cancer Research Center of Russia, Moscow,. Russia 
Two hundred and sixty episodes of FN in 149 children 
(aged 1.5-16 years), with acute myeloblastic leukemia 
(AML-43 cases) and acute lymphoblastic leukemia 
(ALL-106 cases) during the last 10 years were analyzed. 
Cytostatic therapy consist of mBFM-87 AML and 
mBFM-90 ALL protocols. The fourth degree of FN 
occured in 90% of cases of AML and in 53% of 
ALL. The infection sites\diseases were: blood + central 
venous catheter 12.3%, respiratory tract (pneumonias) 
18.8%, enteritidis 8.1%, stomatitis 5.4%, soft tissue 
abscesses 4.2%, acute otitis- 1.9%, pyelonephritis 0.8%, 
viral infection 3.1%. FUO was found in 45.3% of cases. 
Pathogens (91 strains) isolated from blood (and central 
venous catheters) for the last 10 years were: Gram (+) 
64%, Gram (-) 29%, Fungi 7%. CNS were isolated 
in 64%, Streptococcus spp. in 14%, S.aureus in 22% of 
cases among Gram (+) pathogens. Gram (-) strains 
were: KES 41%, P aeruginosa 23%, other 36%. Fungi 
consisted of Candida spp. mainly, Aspergillus spp. were 
found in 5.9% of cases. The number of MRSA and MR- 
CNS isolated from all pathological materials were 25% 
and 70%. The level of this pathogens was significantly 
higher (p<O,OOl)in 1990-1995 than in 1996-2000: 9% vs 
25% for MRSA and 7% vs 70% for MR-CNS. For the 
empirical treatment of FN standard antimicrobial 
regimens were used: 1st line carbapenems or ceftazidime 
or cefepime, 2nd line vancomicin, 3rd line ampho B were 
used in recommended for this patients doses. Clinical 
efficacy of the 1st line was: 57% and 60% ( ALL) vs 31% 
and 33% (AML) after cephalosporin’s 3-4 generation 
and carbapenem’s used respectively. The clinical result 
for the 2nd line was: 28% for ALL and 50% for AML. 
The 3rd line of therapy demonstrated very high response 
rate for ampho B: 91% for ALL and 80% for AML. 32% 
of children with AML and 5.2% children with ALL died 
because of sepsis. The investigation of viral infections 
shows that 100% of patients were infected with VEB 
and HV-6 type with a clinical symptoms in 23.8% of 
them. 4.8% of patients were infected by CMV. The 
treatment with ganciclovir was successful in all cases. 
Thus, abovementioned treatment of FN in children 
with ALL and AML show very high efficacy of this 
treatment. Very high rate of death for AML children 
make sense that the combination of vancomycin and 
ampho B at the 2nd line of therapy are useful. 
A six-year surveillance of antimicrobial 
resistance of Pseudomonas aeruginosa to 
ceftazidime compared to other anthnicrobials 
in a cancer hospital 
I. N. Petoukhova, N. I/: Dmitrieva 
Cancer Research Center of Russia, Moscow, Russia 
Resistance patterns of 822 strains of P aeruginosa iso- 
lated from cancer patients in 1996-2001 were analysed. 
Resistance to widely used antimicrobial - ceftazidime 
(CAZ) - was 29.5% in 1996-1997; 31.5% in 1998-1999 
and 22.3% in 2000-2001 (p<O.Ol-0.001). Decreasing 
of resistance level to CAZ may be explained by in- 
creasing usage of cefepime (CPM) in the last 2.5 years. 
Resistance of I! aeruginosa to CPM in 2000-2001 didn’t 
differ significantly from that of CAZ (17.2% vs 22.3%, 
p>O.O5). Imipenem (IMP) in 2000-2001 was significantly 
more active compared to CAZ (12.9% vs 22.3%, 
p<O.OOOl). Higher level of resistance of P aeruginosa 
compared to CAZ was seen in 2000-2001 to cefo- 
perazone (49.4% vs 22.3%,p<O.OOOl),amikacin (43.0% 
vs 22.3%, p<O.OOOl), ciprofloxacin (57.5% vs 22.3%, 
p<O,OOOl) andmeropenem (39.3% vs22.3%,p<O.O001). 
Resistance rate to last three antimicrobials increased 
during last 6 years: amikacin - from 16.7% to 43.0%, 
ciprofloxacin - from 28.9% to 57.5%) and meropenem 
-from 17.8% to 39.3% (p<O.OOOl for all comparisons). 
Resistance rate of I! aeruginosa to CAZ during 
2000-2001 was the highest in ICU compared to all 
departments of the hospital (33.3% vs 22.3%,p<O.O1). 
Higher rate of resistant strains of P aeruginosa was 
found in 2000-2001 in bronchoscopic materials (34.3%, 
~~0.02) than in other ones. Thus, the surveillance 
data show that only three from above mentioned 
antimicrobials (CAZ, CPM, IMP) maintain their activity 
against P aeruginosa strains isolated from cancer patients 
in our hospital. Massive usage of other antibiotics such 
as amikacin, ciprofloxacin and meropenem resulted 
in progressive loss of susceptibility to them. Probably 
rational restriction policy is needed. 
